Trial Profile
Trial of OS 2966 in patients with Ebola virus infections in West Africa
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2015
Price :
$35
*
At a glance
- Drugs OS 2966 (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- Sponsors OncoSynergy
- 05 Jan 2015 New trial record
- 16 Dec 2014 This study will be conducted in West Africa, according to a media release from CMC Biologics and OncoSynergy.